SCHEMBL24258084

SCHEMBL24258084

O=c1ccc(-c2noc(Cc3ccccc3)n2)c[nH]1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR1 P21453 2/20 0.58
L3MBTL1 Q9Y468 7/20 0.53
NPC1 O15118 6/20 0.53
RAB9A P51151 6/20 0.53
SMN1; SMN2 Q16637 4/20 0.53
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
TDP1 Q9NUW8 4/20 0.50
ALDH1A1 P00352 2/20 0.50
CYP1A2 P05177 1/20 0.48
CYP2C19 P33261 1/20 0.48
NAMPT P43490 1/20 0.47
PSEN1 P49768 1/20 0.44
PSEN2 P49810 1/20 0.44
APH1B Q8WW43 1/20 0.44
NCSTN Q92542 1/20 0.44
APH1A Q96BI3 1/20 0.44
PSENEN Q9NZ42 1/20 0.44
SMPD1 P17405 1/20 0.44
ATM Q13315 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24258048 0.87 TDP1 (0.57) L3MBTL1NPC1RAB9ASMN1; SMN2MEN1
SCHEMBL24258072 0.87 MAPK1 (0.58) L3MBTL1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL24258021 0.85 ERCC1 (0.48) S1PR1L3MBTL1NPC1RAB9ASMN1; SMN2
SCHEMBL24258023 0.83 S1PR1 (0.43) S1PR1L3MBTL1NPC1RAB9ASMN1; SMN2
SCHEMBL24258053 0.81 ERCC1 (0.49) S1PR1L3MBTL1NPC1RAB9ASMN1; SMN2
SCHEMBL24258039 0.79 ERCC1 (0.45) S1PR1L3MBTL1NPC1RAB9ASMN1; SMN2
SCHEMBL7598545 0.79 S1PR1 (0.81) S1PR1L3MBTL1NPC1RAB9ASMN1; SMN2
SCHEMBL12171128 0.76 S1PR1 (0.67) S1PR1L3MBTL1NPC1RAB9ASMN1; SMN2
SCHEMBL24258056 0.76 HCAR2 (0.41) S1PR1MEN1KMT2ATDP1ALDH1A1
SCHEMBL24258036 0.76 DAO (0.41) L3MBTL1NPC1RAB9ASMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230265082-A1 SUBSTITUTED 1,2,4-OXADIAZOLES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. 2023-08-24 US disclosed
US-20230265082-A1 SUBSTITUTED 1,2,4-OXADIAZOLES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. 2023-08-24 US disclosed
WO-2022035805-A1 SUBSTITUTED 1,2,4-OXADIAZOLES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230265082-A1 SUBSTITUTED 1,2,4-OXADIAZOLES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 USP28, USP1, USP18 S1PR1 4154/4885L3MBTL1 2749/4885NPC1 887/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.